Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, ArcticDx Settle IP Litigation

NEW YORK (GenomeWeb News) – Sequenom and ArcticDx have settled their IP dispute, Sequenom disclosed in its Form 10-Q filed on Thursday.

The firms have reached a settlement agreement and are asking the US District Court, Eastern District of Texas Marshall Division to dismiss the lawsuit filed by ArcticDx earlier this year, Sequenom said in its document filed with the US Securities and Exchange Commission.

The disputed patents relate to adult macular degeneration testing technology.

In the lawsuit, Canadian molecular diagnostics firm ArcticDx accused Sequenom and its Sequenom Center for Molecular Medicine subsidiary of infringing US Patent 8,114,592, licensed by ArcticDx from Cambridge Enterprise. It also asked the court to find that it did not infringe on five patents held by Sequenom — US Patents 8,053,190; 7,867,727; 7,695,909; 7,351,524; and 8,088,579.

Terms of the settlement were not disclosed. Sequenom said that the terms of the settlement are "immaterial" to its financial position, liquidity, and results of operations.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.